Soliqua® 100/33 (insulin glargine and lixisenatide) – Expanded indication
February 27, 2019 - Sanofi announced the FDA approval of Soliqua 100/33 (insulin glargine and lixisenatide), as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Download PDF
